Fate Therapeutics (FATE) Share-based Compensation (2012 - 2026)
Fate Therapeutics (FATE) posted Share-based Compensation of $3.9 million for Q1 2026, down 28.93% on a QoQ basis from $5.5 million in Q4 2025, and down 46.77% year-over-year from $7.4 million in Q1 2025.
Fate Therapeutics (FATE) Share-based Compensation (2012 - 2026) Analysis & Trends
Fate Therapeutics' Share-based Compensation history runs 15 years deep, the most recent figure standing at $3.9 million for Q1 2026.
- Quarterly Share-based Compensation fell 46.77% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.5 million (down 43.34% YoY) and the FY2025 annual result came in at $24.9 million, down 39.94% from the prior year.
- Share-based Compensation was $3.9 million for Q1 2026 at Fate Therapeutics, down from $5.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $78.1 million in Q4 2022 and bottomed at $558000.0 in Q1 2024.
- A 5-year average of $14.2 million and a median of $9.6 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation sank 94.92% — and 2025, when it soared 1222.76%.
- Fate Therapeutics' Share-based Compensation stood at $78.1 million in 2022, then slumped by 87.86% to $9.5 million in 2023, then retreated by 3.75% to $9.1 million in 2024, then sank by 39.39% to $5.5 million in 2025, then slipped by 28.93% to $3.9 million in 2026.
- Business Quant data shows FATE's Share-based Compensation at $3.9 million in Q1 2026, $5.5 million in Q4 2025, and $4.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - | 3.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.93 Mn |
| Mar 31, 2026 | 3.93 Mn |
| Dec 31, 2025 | 5.53 Mn |
| Dec 31, 2025 | 5.53 Mn |
| Sep 30, 2025 | 4.86 Mn |
| Sep 30, 2025 | 4.86 Mn |
| Jun 30, 2025 | 7.15 Mn |
| Jun 30, 2025 | 7.15 Mn |
| Mar 31, 2025 | 7.38 Mn |
| Mar 31, 2025 | 7.38 Mn |
| Dec 31, 2024 | 9.12 Mn |
| Dec 31, 2024 | 9.12 Mn |
| Sep 30, 2024 | 11.77 Mn |
| Sep 30, 2024 | 11.77 Mn |
| Jun 30, 2024 | 9.63 Mn |
| Jun 30, 2024 | 9.63 Mn |
| Mar 31, 2024 | 558,000.00 |
| Mar 31, 2024 | 558,000.00 |
| Dec 31, 2023 | 9.48 Mn |
| Dec 31, 2023 | 9.48 Mn |